2020
SARS-CoV-2 detection in setting of viral swabs scarcity: Are MRSA swabs and viral swabs equivalent?
Federman DG, Gupta S, Stack G, Campbell SM, Peaper DR, Dembry LM, Fisher A, Tarabar AF, Kozal M, Ruser CB. SARS-CoV-2 detection in setting of viral swabs scarcity: Are MRSA swabs and viral swabs equivalent? PLOS ONE 2020, 15: e0237127. PMID: 32756602, PMCID: PMC7406068, DOI: 10.1371/journal.pone.0237127.Peer-Reviewed Original ResearchConceptsMRSA swabsViral swabSARS-CoV-2 PCR testingCopan ESwabSevere acute respiratory syndromeMRSA nasal swabSARS-CoV-2 assayAcute respiratory syndromeCOVID-19SARS-CoV-2SARS-CoV-2 detectionNasopharyngeal swabsCoronavirus 2Nasal swabsRespiratory syndromePCR testingSwab collectionSwabsSwab samplesCepheid Xpert XpressXpert XpressWidespread testingCollection kitHealthcare systemViral media
2009
Raltegravir With Unboosted Atazanavir 300 mg Twice Daily in Antiretroviral Treatment-Experienced Participants
Gupta S, Lataillade M, Farber S, Kozal MJ. Raltegravir With Unboosted Atazanavir 300 mg Twice Daily in Antiretroviral Treatment-Experienced Participants. Journal Of The International Association Of Providers Of AIDS Care (JIAPAC) 2009, 8: 87-92. PMID: 19270153, DOI: 10.1177/1545109709332471.Peer-Reviewed Original ResearchConceptsMean CD4 count increaseCD4 count increaseCombination of raltegravirTreatment-experienced patientsPotent antiretroviral activityCopies/mLProtease inhibitorsARV agentsUnboosted atazanavirHIV RNAImmunologic outcomesTwice DailyAntiretroviral treatmentARV therapyAntiretroviral agentsCase seriesHIV integrase inhibitorsTherapeutic failureAntiretroviral activityRaltegravirAtazanavirIntegrase inhibitorsAdverse effectsCells/Count increase